Aide Health: platform trialled by NHS gets £1m cash injection
Remote health platform Aide Health has secured $1.2m (£1m) in pre-seed capital, in a round led by Hambro Perks’ EIS fund.
Medical professionals can use Aide Health’s platform to remotely monitor patients with chronic diseases such as type-2 diabetes, heart disease, asthma, and IBD. Patients monitored through the app can also receive medical advice.
The London-headquartered startup was launched last year by co-founders Ian Wharton and Brian Snyde.
“Like many people, I know first-hand the frustrations of trying to manage long-term conditions,” said Wharton, CEO of Aide Health.
“Our goal is to give both patients and clinicians the tools and insights they need to have better conversations and make more informed treatment decisions together.”
The NHS is currently trialling the health tech startup’s platform for people with asthma and type-2 diabetes aged 18-75.
With the additional capital, the firm plans on expanding its services to include hypertension and chronic pain.
Nicholas Sharp, head of the Hambro Perks Growth EIS Fund, said: “Ian and Brian’s vision and experience impressed us from the start, and we believe that Aide Health has the potential to be a hugely important tool for both clinicians and patients for managing long-term health conditions.”
Hambro Perks was joined by Fuel Ventures, 1818 Ventures and APX as investors in the Aide Health pre-seed round.